Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc., has reported several stock transactions in a recent filing. This update is significant as it sheds light on the financial activities of a key executive in the pharmaceutical industry.

Background

Nurix Therapeutics, Inc. is a company focused on developing innovative therapies in the pharmaceutical sector. The company operates under the SIC code for Pharmaceutical Preparations. The recent filing by van Houte is part of a series of disclosures that highlight the ongoing financial activities of its executives. The company has been active in reporting various transactions, with the latest filing dated November 2, 2026.

What the Filing Says

The filing indicates that van Houte executed multiple transactions on October 30, 2026. Notably, he acquired a total of 10,182 shares of common stock, including 3,750 shares through restricted stock units. Additionally, he disposed of 2,834 shares at an average price of $26.2791 to cover tax withholding obligations related to the vesting of these units. The filing states, "The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units." This transaction highlights the financial management strategies employed by executives in the pharmaceutical sector.

Impact

These transactions may impact various stakeholders, including investors and corporate governance bodies. The disclosure of stock transactions by executives like van Houte can influence investor confidence and perceptions of the company's management practices. As Nurix Therapeutics continues to navigate the competitive pharmaceutical landscape, such disclosures are crucial for maintaining transparency and trust among shareholders.

What's Next

The filing does not say what happens next.